CU24609B1 - Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic - Google Patents
Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de micInfo
- Publication number
- CU24609B1 CU24609B1 CU2018000050A CU20180050A CU24609B1 CU 24609 B1 CU24609 B1 CU 24609B1 CU 2018000050 A CU2018000050 A CU 2018000050A CU 20180050 A CU20180050 A CU 20180050A CU 24609 B1 CU24609 B1 CU 24609B1
- Authority
- CU
- Cuba
- Prior art keywords
- protein
- domain
- ferritin subunit
- fusion protein
- linked
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 101710157275 Ferritin subunit Proteins 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 239000002105 nanoparticle Substances 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263377P | 2015-12-04 | 2015-12-04 | |
| US201662422454P | 2016-11-15 | 2016-11-15 | |
| PCT/US2016/064969 WO2017096374A1 (en) | 2015-12-04 | 2016-12-05 | Vaccination with mica/b alpha 3 domain for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20180050A7 CU20180050A7 (es) | 2018-11-06 |
| CU24609B1 true CU24609B1 (es) | 2022-06-06 |
Family
ID=57590885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2018000050A CU24609B1 (es) | 2015-12-04 | 2016-12-05 | Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic |
| CU2021000061A CU20210061A7 (es) | 2015-12-04 | 2016-12-05 | Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2021000061A CU20210061A7 (es) | 2015-12-04 | 2016-12-05 | Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10993971B2 (enExample) |
| EP (1) | EP3383426A1 (enExample) |
| JP (3) | JP7099956B2 (enExample) |
| KR (1) | KR20180088458A (enExample) |
| CN (1) | CN108770343A (enExample) |
| AU (3) | AU2016362597C1 (enExample) |
| BR (1) | BR112018010705A8 (enExample) |
| CA (1) | CA3005910A1 (enExample) |
| CL (3) | CL2018001470A1 (enExample) |
| CO (1) | CO2018006642A2 (enExample) |
| CR (2) | CR20180350A (enExample) |
| CU (2) | CU24609B1 (enExample) |
| EA (1) | EA201891287A1 (enExample) |
| IL (1) | IL259490A (enExample) |
| MX (2) | MX2018006785A (enExample) |
| MY (1) | MY199248A (enExample) |
| NZ (1) | NZ742663A (enExample) |
| PE (2) | PE20181158A1 (enExample) |
| PH (1) | PH12018501170A1 (enExample) |
| RU (2) | RU2021109510A (enExample) |
| SG (1) | SG11201804597TA (enExample) |
| TN (1) | TN2018000187A1 (enExample) |
| WO (1) | WO2017096374A1 (enExample) |
| ZA (1) | ZA202204223B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021519599A (ja) | 2018-04-03 | 2021-08-12 | サノフイＳａｎｏｆｉ | 抗原性ｏｓｐａポリペプチド |
| JP7614842B2 (ja) | 2018-04-03 | 2025-01-16 | サノフイ | 抗原性エプスタインバーウイルスポリペプチド |
| KR20210018206A (ko) | 2018-04-03 | 2021-02-17 | 사노피 | 항원성 호흡기 세포융합 바이러스 폴리펩타이드 |
| JP2021519596A (ja) * | 2018-04-03 | 2021-08-12 | サノフイＳａｎｏｆｉ | フェリチンタンパク質 |
| WO2021174132A2 (en) * | 2020-02-26 | 2021-09-02 | The Wistar Institute Of Anatomy & Biology | Compositions comprising self-assembling vaccines and methods of using the same |
| KR102594083B1 (ko) | 2020-07-07 | 2023-10-25 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
| CN116396398B (zh) * | 2023-01-16 | 2024-07-16 | 四川大学 | 一种实现铁蛋白纳米颗粒可控自组装的方法以及基于该方法搭建的纳米颗粒抗原展示平台 |
| WO2024222886A1 (zh) * | 2023-04-28 | 2024-10-31 | 北京先声祥瑞生物制品股份有限公司 | 一种针对MICA/B靶点的mRNA肿瘤疫苗 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
| US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| EP0378881B1 (en) | 1989-01-17 | 1993-06-09 | ENIRICERCHE S.p.A. | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| FI920131A0 (fi) | 1989-07-14 | 1992-01-13 | Praxis Biolog Inc | Cytokin- och hormonbaerare foer konjugatvaccin. |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| DE69113564T2 (de) | 1990-08-13 | 1996-05-30 | American Cyanamid Co | Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff. |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| ES2130265T3 (es) | 1992-05-06 | 1999-07-01 | Harvard College | Region de union al receptor de la toxina difterica. |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| PT942983E (pt) | 1996-10-31 | 2007-02-28 | Human Genome Sciences Inc | Antigénios e vacinas de streptococcus pneumoniae |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| KR100642044B1 (ko) | 1999-03-19 | 2006-11-10 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| EP1165796A2 (en) | 1999-04-09 | 2002-01-02 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
| CA2776391C (en) | 2001-10-01 | 2015-03-31 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
| US6706305B2 (en) | 2001-10-31 | 2004-03-16 | Conagra Foods Inc. | Low glycemic index bread |
| CA2485363C (en) * | 2002-05-10 | 2014-10-28 | New Century Pharmaceuticals, Inc. | Ferritin fusion proteins for use in vaccines and other applications |
| US20090104170A1 (en) | 2004-11-02 | 2009-04-23 | Richard William Wyatt Childs | Compositions and methods for treating hyperproliferative disorders |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| US8110196B2 (en) | 2005-04-29 | 2012-02-07 | Polytopas LLC | Methods and compositions for polytopic vaccination |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| EP2083857A4 (en) | 2006-09-22 | 2010-03-24 | Dana Farber Cancer Res Inc | METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA |
| US8182809B1 (en) * | 2008-09-08 | 2012-05-22 | University Of Washington | Methods for treating cancer by inhibiting MIC shedding |
| WO2011046842A1 (en) | 2009-10-12 | 2011-04-21 | The Regents Of The University Of California | Targeted nanoclusters and methods of their use |
| WO2011074573A1 (ja) | 2009-12-18 | 2011-06-23 | 花王株式会社 | メソポーラスシリカ粒子の製造方法 |
| JP5603063B2 (ja) | 2009-12-21 | 2014-10-08 | 花王株式会社 | 複合シリカ粒子の製造方法 |
| RU2489169C2 (ru) * | 2010-10-12 | 2013-08-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) | Способ лечения онкологических заболеваний |
| WO2013041966A1 (en) * | 2011-09-23 | 2013-03-28 | University Of Oslo | Vaccibodies targeted to cross-presenting dendritic cells |
| EP2760471B9 (en) | 2011-09-30 | 2017-07-19 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| CA2862101A1 (en) * | 2012-02-07 | 2013-08-15 | Innate Pharma | Mica binding agents |
| PT2838515T (pt) | 2012-04-16 | 2020-02-25 | Harvard College | Composições de sílica mesoporosa para modular respostas imunológicas |
| US10851148B2 (en) | 2013-03-15 | 2020-12-01 | Novelogics Biotechnology, Inc. | Antibodies to MICA and MICB proteins |
| CA2907249A1 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| WO2015139020A2 (en) * | 2014-03-14 | 2015-09-17 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
-
2016
- 2016-12-05 NZ NZ742663A patent/NZ742663A/en unknown
- 2016-12-05 CU CU2018000050A patent/CU24609B1/es unknown
- 2016-12-05 AU AU2016362597A patent/AU2016362597C1/en active Active
- 2016-12-05 JP JP2018528691A patent/JP7099956B2/ja active Active
- 2016-12-05 EP EP16816550.4A patent/EP3383426A1/en active Pending
- 2016-12-05 CR CR20180350A patent/CR20180350A/es unknown
- 2016-12-05 SG SG11201804597TA patent/SG11201804597TA/en unknown
- 2016-12-05 WO PCT/US2016/064969 patent/WO2017096374A1/en not_active Ceased
- 2016-12-05 US US15/781,448 patent/US10993971B2/en active Active
- 2016-12-05 MY MYPI2018000849A patent/MY199248A/en unknown
- 2016-12-05 RU RU2021109510A patent/RU2021109510A/ru unknown
- 2016-12-05 CA CA3005910A patent/CA3005910A1/en active Pending
- 2016-12-05 EA EA201891287A patent/EA201891287A1/ru unknown
- 2016-12-05 PE PE2018001072A patent/PE20181158A1/es unknown
- 2016-12-05 CU CU2021000061A patent/CU20210061A7/es unknown
- 2016-12-05 MX MX2018006785A patent/MX2018006785A/es unknown
- 2016-12-05 RU RU2018123307A patent/RU2747296C2/ru active
- 2016-12-05 CR CR20230116A patent/CR20230116A/es unknown
- 2016-12-05 CN CN201680080434.4A patent/CN108770343A/zh active Pending
- 2016-12-05 BR BR112018010705A patent/BR112018010705A8/pt active Search and Examination
- 2016-12-05 PE PE2022002801A patent/PE20230495A1/es unknown
- 2016-12-05 KR KR1020187019140A patent/KR20180088458A/ko not_active Ceased
- 2016-12-05 TN TNP/2018/000187A patent/TN2018000187A1/en unknown
-
2018
- 2018-05-21 IL IL259490A patent/IL259490A/en unknown
- 2018-06-01 MX MX2022010194A patent/MX2022010194A/es unknown
- 2018-06-01 PH PH12018501170A patent/PH12018501170A1/en unknown
- 2018-06-01 CL CL2018001470A patent/CL2018001470A1/es unknown
- 2018-06-27 CO CONC2018/0006642A patent/CO2018006642A2/es unknown
-
2021
- 2021-02-19 US US17/180,183 patent/US20210299186A1/en not_active Abandoned
- 2021-05-13 CL CL2021001256A patent/CL2021001256A1/es unknown
-
2022
- 2022-03-21 AU AU2022201940A patent/AU2022201940B2/en active Active
- 2022-04-14 ZA ZA2022/04223A patent/ZA202204223B/en unknown
- 2022-06-30 JP JP2022105405A patent/JP7564842B2/ja active Active
-
2023
- 2023-10-26 CL CL2023003217A patent/CL2023003217A1/es unknown
-
2024
- 2024-02-19 US US18/581,148 patent/US20250064863A1/en active Pending
- 2024-09-27 JP JP2024167997A patent/JP2024177207A/ja active Pending
-
2025
- 2025-08-08 AU AU2025213685A patent/AU2025213685A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24609B1 (es) | Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic | |
| EP4442816A3 (en) | Mutated glycoprotein of vesicular stomatitis virus | |
| PE20240015A1 (es) | Proteinas de fusion gdf15 y usos de estas | |
| UA118167C2 (uk) | Пептид та його застосування | |
| PE20181354A1 (es) | Mutantes de proteina f de rsv | |
| MX394191B (es) | Composiciones para el cuidado bucal y metodos de uso | |
| ES2691091T3 (es) | Vacuna conjugada de péptido antigénico de WT1 | |
| CO2017005995A2 (es) | Composiciones para el cuidado bucal y métodos de uso | |
| EA201990071A1 (ru) | Композиция пептидной вакцины | |
| PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| PE20161442A1 (es) | Proteinas quimericas tipo fosfatasa alcalina | |
| PL393578A1 (pl) | Przeciwnowotworowe białko fuzyjne | |
| EA201491049A1 (ru) | Противораковый слитый белок | |
| EA201491277A1 (ru) | Противораковый слитый белок | |
| EA201990298A1 (ru) | Способы и композиции для лечения рака | |
| PE20151978A1 (es) | Composiciones nutricionales que contienen un componente peptidico con propiedades antinflamatorias y usos del mismo | |
| MX2019006943A (es) | Polipéptidos para manejo de infecciones virales. | |
| AR128395A2 (es) | Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9 | |
| EP3360895A3 (en) | Preparation comprising factor viii and von willebrand factor peptides | |
| BR112014028130A2 (pt) | Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos | |
| EA201991702A1 (ru) | Самосборные белковые наночастицы, инкапсулирующие иммуностимулирующие нуклеиновые кислоты | |
| AR132574A2 (es) | UN PÉPTIDO DE FUSIÓN QUE COMPRENDE UNA ISOFORMA DEL RECEPTOR II DE TGF b FUSIONADA A UN LIGANDO, POLINUCLEÓTIDO QUE LO EXPRESA, VECTOR Y CÉLULA | |
| BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 | |
| MX420767B (es) | Proteina de union al factor h modificada | |
| MX362058B (es) | Péptido pntx(19) sintético, composición farmacéutica y uso. |